Jupiter Neurosciences, Inc. (JUNS)
NASDAQ:JUNS
JUNS Stock Chart & Stats
$0.44
<$0.01(0.12%)
At close: 4:00 PM EST
$0.44
<$0.01(0.12%)
Day’s Range― - ―
52-Week Range$0.17 - $3.33
Previous CloseN/A
Volume197.86K
Average Volume (3M)148.03K
Market Cap
$11.48M
Enterprise Value$10.82M
Total Cash (Recent Filing)$2.36M
Total Debt (Recent Filing)$4.83M
Price to Earnings (P/E)―
Beta0.68
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding48,224,110
10 Day Avg. Volume107,563
30 Day Avg. Volume148,028
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-19.28
Price to Sales (P/S)1620.53
P/FCF Ratio-6.52
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue267.41
Enterprise Value/Gross Profit299.73
Enterprise Value/Ebitda-1.20
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering0
EPS Forecast (FY)0.06
Revenue Forecast (FY)$12.13M
Jupiter Neurosciences, Inc. News
JUNS FAQ
What was Jupiter Neurosciences, Inc.’s price range in the past 12 months?
Jupiter Neurosciences, Inc. lowest stock price was $0.17 and its highest was $3.33 in the past 12 months.
What is Jupiter Neurosciences, Inc.’s market cap?
Jupiter Neurosciences, Inc.’s market cap is $11.48M.
When is Jupiter Neurosciences, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Jupiter Neurosciences, Inc.’s earnings last quarter?
Currently, no data Available
Is Jupiter Neurosciences, Inc. overvalued?
According to Wall Street analysts Jupiter Neurosciences, Inc.’s price is currently Overvalued.
Does Jupiter Neurosciences, Inc. pay dividends?
Jupiter Neurosciences, Inc. does not currently pay dividends.
What is Jupiter Neurosciences, Inc.’s EPS estimate?
Jupiter Neurosciences, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Jupiter Neurosciences, Inc. have?
Jupiter Neurosciences, Inc. has 48,224,110 shares outstanding.
What happened to Jupiter Neurosciences, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Jupiter Neurosciences, Inc.?
Currently, no hedge funds are holding shares in JUNS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Jupiter Neurosciences, Inc.
Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in clinical-stage research and development. Its primary focus is on advancing a resveratrol-based platform product, with the main objective of addressing neuro-inflammation. The company's pipeline includes several drug candidates: JNS101 is undergoing Phase II trials for Friedreich's Ataxia, a rare neurological disorder that damages the nervous system and causes mobility issues. Also in Phase II, JNS102 is being developed for mucopolysaccharidosis Type I, JNS107 for MELAS Syndrome, and JNS108 for mild cognitive impairment and early Alzheimer's disease. Furthermore, the company is progressing JNS109 for amyotrophic lateral sclerosis, JNS110 for traumatic brain injury and concussion, and JNS120 as a treatment for COVID-19. Founded in 2016, the company, formerly known as Jupiter Orphan Therapeutics, Inc., adopted its current name in August 2021 and is headquartered in Jupiter, Florida.
Technical Analysis
Relmada Therapeutics
―
Gain Therapeutics
―
MiNK Therapeutics
―
Adlai Nortye Ltd. Sponsored ADR
―
OS Therapies Incorporated
―
Ownership Overview
23.41% Insiders
1.01% Mutual Funds
2.28% Other Institutional Investors
72.96% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---